CDH13 polymorphisms are associated with adiponectin levels and metabolic syndrome traits independently of visceral fat mass

Aya Kitamoto, Takuya Kitamoto, Takahiro Nakamura, Tomoaki Matsuo, Yoshio Nakata, Hideyuki Hyogo, Hidenori Ochi, Seika Kamohara, Nobuyuki Miyatake, Kazuaki Kotani, Ikuo Mineo, Jun Wada, Yuji Ogawa, Masato Yoneda, Atsushi Nakajima, Tohru Funahashi, Shigeru Miyazaki, Katsuto Tokunaga, Hiroaki Masuzaki, Takato UenoKazuaki Chayama, Kazuyuki Hamaguchi, Kentaro Yamada, Toshiaki Hanafusa, Shinichi Oikawa, Toshiie Sakata, Kiyoji Tanaka, Yuji Matsuzawa, Kikuko Hotta

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Aim: Visceral fat accumulation contributes to the development of metabolic syndrome. As visceral fat accumulation increases, adiponectin levels decrease; therefore, adiponectin provides a link between visceral fat accumulation and metabolic disorders. Genome-wide association studies (GWASs) have identified genetic variations in the cadherin 13 (CDH13) gene that are associated with adiponectin levels. Methods: We investigated whether single nucleotide polymorphisms (SNPs) in CDH13 was associated with adiponectin levels and metabolic syndrome traits independent of the visceral fat area (VFA), as measured using computed tomography (CT) in 945 Japanese individuals. Results: We found that three CDH13 SNPs reported by recent GWASs (i.e., rs3865188, rs4783244, and rs12051272) were significantly associated with higher adiponectin levels (P-14), even after adjustment for VFA. However, these adiponectin-inducing alleles of CDH13 SNPs were significantly associated with traits consistent with deteriorating metabolic symptoms, such as higher fasting insulin, homeostasis model assessment–insulin resistance (HOMA-IR) scores, and triglycerides and lower highdensity lipoprotein (HDL)-cholesterol levels, similar to increasing VFA and decreasing adiponectin levels. Conclusion: These results suggested that CDH13 SNPs cause an adiponectin-resistant status to compensate for increasing adiponectin levels and could result in the deterioration of metabolic syndrome traits.

Original languageEnglish
Pages (from-to)309-319
Number of pages11
JournalJournal of Atherosclerosis and Thrombosis
Volume23
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Intra-Abdominal Fat
Adiponectin
Polymorphism
Fats
Single Nucleotide Polymorphism
Nucleotides
Genes
Genome-Wide Association Study
H-cadherin
Tomography
Deterioration
Fasting
Triglycerides
Homeostasis
Alleles
Insulin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine
  • Biochemistry, medical

Cite this

CDH13 polymorphisms are associated with adiponectin levels and metabolic syndrome traits independently of visceral fat mass. / Kitamoto, Aya; Kitamoto, Takuya; Nakamura, Takahiro; Matsuo, Tomoaki; Nakata, Yoshio; Hyogo, Hideyuki; Ochi, Hidenori; Kamohara, Seika; Miyatake, Nobuyuki; Kotani, Kazuaki; Mineo, Ikuo; Wada, Jun; Ogawa, Yuji; Yoneda, Masato; Nakajima, Atsushi; Funahashi, Tohru; Miyazaki, Shigeru; Tokunaga, Katsuto; Masuzaki, Hiroaki; Ueno, Takato; Chayama, Kazuaki; Hamaguchi, Kazuyuki; Yamada, Kentaro; Hanafusa, Toshiaki; Oikawa, Shinichi; Sakata, Toshiie; Tanaka, Kiyoji; Matsuzawa, Yuji; Hotta, Kikuko.

In: Journal of Atherosclerosis and Thrombosis, Vol. 23, No. 3, 01.03.2016, p. 309-319.

Research output: Contribution to journalArticle

Kitamoto, A, Kitamoto, T, Nakamura, T, Matsuo, T, Nakata, Y, Hyogo, H, Ochi, H, Kamohara, S, Miyatake, N, Kotani, K, Mineo, I, Wada, J, Ogawa, Y, Yoneda, M, Nakajima, A, Funahashi, T, Miyazaki, S, Tokunaga, K, Masuzaki, H, Ueno, T, Chayama, K, Hamaguchi, K, Yamada, K, Hanafusa, T, Oikawa, S, Sakata, T, Tanaka, K, Matsuzawa, Y & Hotta, K 2016, 'CDH13 polymorphisms are associated with adiponectin levels and metabolic syndrome traits independently of visceral fat mass', Journal of Atherosclerosis and Thrombosis, vol. 23, no. 3, pp. 309-319. https://doi.org/10.5551/jat.31567
Kitamoto, Aya ; Kitamoto, Takuya ; Nakamura, Takahiro ; Matsuo, Tomoaki ; Nakata, Yoshio ; Hyogo, Hideyuki ; Ochi, Hidenori ; Kamohara, Seika ; Miyatake, Nobuyuki ; Kotani, Kazuaki ; Mineo, Ikuo ; Wada, Jun ; Ogawa, Yuji ; Yoneda, Masato ; Nakajima, Atsushi ; Funahashi, Tohru ; Miyazaki, Shigeru ; Tokunaga, Katsuto ; Masuzaki, Hiroaki ; Ueno, Takato ; Chayama, Kazuaki ; Hamaguchi, Kazuyuki ; Yamada, Kentaro ; Hanafusa, Toshiaki ; Oikawa, Shinichi ; Sakata, Toshiie ; Tanaka, Kiyoji ; Matsuzawa, Yuji ; Hotta, Kikuko. / CDH13 polymorphisms are associated with adiponectin levels and metabolic syndrome traits independently of visceral fat mass. In: Journal of Atherosclerosis and Thrombosis. 2016 ; Vol. 23, No. 3. pp. 309-319.
@article{751711e791fc4a38a98107e6868f01c4,
title = "CDH13 polymorphisms are associated with adiponectin levels and metabolic syndrome traits independently of visceral fat mass",
abstract = "Aim: Visceral fat accumulation contributes to the development of metabolic syndrome. As visceral fat accumulation increases, adiponectin levels decrease; therefore, adiponectin provides a link between visceral fat accumulation and metabolic disorders. Genome-wide association studies (GWASs) have identified genetic variations in the cadherin 13 (CDH13) gene that are associated with adiponectin levels. Methods: We investigated whether single nucleotide polymorphisms (SNPs) in CDH13 was associated with adiponectin levels and metabolic syndrome traits independent of the visceral fat area (VFA), as measured using computed tomography (CT) in 945 Japanese individuals. Results: We found that three CDH13 SNPs reported by recent GWASs (i.e., rs3865188, rs4783244, and rs12051272) were significantly associated with higher adiponectin levels (P-14), even after adjustment for VFA. However, these adiponectin-inducing alleles of CDH13 SNPs were significantly associated with traits consistent with deteriorating metabolic symptoms, such as higher fasting insulin, homeostasis model assessment–insulin resistance (HOMA-IR) scores, and triglycerides and lower highdensity lipoprotein (HDL)-cholesterol levels, similar to increasing VFA and decreasing adiponectin levels. Conclusion: These results suggested that CDH13 SNPs cause an adiponectin-resistant status to compensate for increasing adiponectin levels and could result in the deterioration of metabolic syndrome traits.",
author = "Aya Kitamoto and Takuya Kitamoto and Takahiro Nakamura and Tomoaki Matsuo and Yoshio Nakata and Hideyuki Hyogo and Hidenori Ochi and Seika Kamohara and Nobuyuki Miyatake and Kazuaki Kotani and Ikuo Mineo and Jun Wada and Yuji Ogawa and Masato Yoneda and Atsushi Nakajima and Tohru Funahashi and Shigeru Miyazaki and Katsuto Tokunaga and Hiroaki Masuzaki and Takato Ueno and Kazuaki Chayama and Kazuyuki Hamaguchi and Kentaro Yamada and Toshiaki Hanafusa and Shinichi Oikawa and Toshiie Sakata and Kiyoji Tanaka and Yuji Matsuzawa and Kikuko Hotta",
year = "2016",
month = "3",
day = "1",
doi = "10.5551/jat.31567",
language = "English",
volume = "23",
pages = "309--319",
journal = "Journal of Atherosclerosis and Thrombosis",
issn = "1340-3478",
publisher = "Japan Atherosclerosis Society",
number = "3",

}

TY - JOUR

T1 - CDH13 polymorphisms are associated with adiponectin levels and metabolic syndrome traits independently of visceral fat mass

AU - Kitamoto, Aya

AU - Kitamoto, Takuya

AU - Nakamura, Takahiro

AU - Matsuo, Tomoaki

AU - Nakata, Yoshio

AU - Hyogo, Hideyuki

AU - Ochi, Hidenori

AU - Kamohara, Seika

AU - Miyatake, Nobuyuki

AU - Kotani, Kazuaki

AU - Mineo, Ikuo

AU - Wada, Jun

AU - Ogawa, Yuji

AU - Yoneda, Masato

AU - Nakajima, Atsushi

AU - Funahashi, Tohru

AU - Miyazaki, Shigeru

AU - Tokunaga, Katsuto

AU - Masuzaki, Hiroaki

AU - Ueno, Takato

AU - Chayama, Kazuaki

AU - Hamaguchi, Kazuyuki

AU - Yamada, Kentaro

AU - Hanafusa, Toshiaki

AU - Oikawa, Shinichi

AU - Sakata, Toshiie

AU - Tanaka, Kiyoji

AU - Matsuzawa, Yuji

AU - Hotta, Kikuko

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Aim: Visceral fat accumulation contributes to the development of metabolic syndrome. As visceral fat accumulation increases, adiponectin levels decrease; therefore, adiponectin provides a link between visceral fat accumulation and metabolic disorders. Genome-wide association studies (GWASs) have identified genetic variations in the cadherin 13 (CDH13) gene that are associated with adiponectin levels. Methods: We investigated whether single nucleotide polymorphisms (SNPs) in CDH13 was associated with adiponectin levels and metabolic syndrome traits independent of the visceral fat area (VFA), as measured using computed tomography (CT) in 945 Japanese individuals. Results: We found that three CDH13 SNPs reported by recent GWASs (i.e., rs3865188, rs4783244, and rs12051272) were significantly associated with higher adiponectin levels (P-14), even after adjustment for VFA. However, these adiponectin-inducing alleles of CDH13 SNPs were significantly associated with traits consistent with deteriorating metabolic symptoms, such as higher fasting insulin, homeostasis model assessment–insulin resistance (HOMA-IR) scores, and triglycerides and lower highdensity lipoprotein (HDL)-cholesterol levels, similar to increasing VFA and decreasing adiponectin levels. Conclusion: These results suggested that CDH13 SNPs cause an adiponectin-resistant status to compensate for increasing adiponectin levels and could result in the deterioration of metabolic syndrome traits.

AB - Aim: Visceral fat accumulation contributes to the development of metabolic syndrome. As visceral fat accumulation increases, adiponectin levels decrease; therefore, adiponectin provides a link between visceral fat accumulation and metabolic disorders. Genome-wide association studies (GWASs) have identified genetic variations in the cadherin 13 (CDH13) gene that are associated with adiponectin levels. Methods: We investigated whether single nucleotide polymorphisms (SNPs) in CDH13 was associated with adiponectin levels and metabolic syndrome traits independent of the visceral fat area (VFA), as measured using computed tomography (CT) in 945 Japanese individuals. Results: We found that three CDH13 SNPs reported by recent GWASs (i.e., rs3865188, rs4783244, and rs12051272) were significantly associated with higher adiponectin levels (P-14), even after adjustment for VFA. However, these adiponectin-inducing alleles of CDH13 SNPs were significantly associated with traits consistent with deteriorating metabolic symptoms, such as higher fasting insulin, homeostasis model assessment–insulin resistance (HOMA-IR) scores, and triglycerides and lower highdensity lipoprotein (HDL)-cholesterol levels, similar to increasing VFA and decreasing adiponectin levels. Conclusion: These results suggested that CDH13 SNPs cause an adiponectin-resistant status to compensate for increasing adiponectin levels and could result in the deterioration of metabolic syndrome traits.

UR - http://www.scopus.com/inward/record.url?scp=84959264340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959264340&partnerID=8YFLogxK

U2 - 10.5551/jat.31567

DO - 10.5551/jat.31567

M3 - Article

C2 - 26423718

AN - SCOPUS:84959264340

VL - 23

SP - 309

EP - 319

JO - Journal of Atherosclerosis and Thrombosis

JF - Journal of Atherosclerosis and Thrombosis

SN - 1340-3478

IS - 3

ER -